Pharma Mar SA · BME:PHM

Pharma Mar SA — Investor Presentation (November 2023)

32 slides from Pharma Mar SA's investor presentation, November 2023

  1. Slide 1: Corporate Presentation

    November 2023 Corporate Presentation World leader in the development and commercialization of anticancer drugs of marine origin

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity, results of operation, clinical program, plans and objectives of Pharma Mar, S.A. ("PharmaMar" or the "Company"). These f

  3. Slide 3: Management Team

    Management Team We are inspired by the sea, driven by science, and motivated to improve the lives of cancer patients by delivering novel medicines. We intend to continue to be the world leader in marine José María Fernández, Ph.D Luis Mora medicinal discovery, development and Chief Executive Officer

  4. Slide 4: Corporate Overview

    Corporate Overview Global Fully Integrated 3 Approved Oncology Commercial Stage Biotech Products Developing marine-inspired oncology drugs Established European oncology sales force Revenue Generating & Profitable Discovery Platform Strengthening Oncology Revenues in 2022 €196.3m Pipeline EBITDA 2022

  5. Slide 5: The Plan for growth

    The Plan for growth On track to deliver value to shareholders Lurbinectedin Other drugs Corporate development development development ✦ Phase 3 trials with Lurbinectedin ✦ 2 Phase 2 trials for Ecubectedin ✦ Looking for in-licensing products in SCLC for EU approval enrolling to market and confirmator

  6. Slide 6: Zepzelca: Transformative for PharmaMar

    Zepzelca: Transformative for PharmaMar License agreement in the US/Canada $200m received upfront ✦ High teens to 30% Royalties on $100m received approval US/Canada sales $25m ✦ Enrollment completion expected received commercial ~YE2023 of Phase 3 in 1L maintenance milestone ES-SCLC in combination wi

  7. Slide 7: Pipeline – Expanding our Expertise in Oncology

    Pipeline – Expanding our Expertise in Oncology Phase 1 Phase 2 Phase 3 Market Soft tissue sarcoma 2nd/3rd line Monotherapy Ovarian cancer 2nd/3rd line + Doxil (PLD) R/R Multiple Myeloma1 3rd/4th line + dexamethasone Small cell lung cancer 2nd line US Monotherapy Small cell lung cancer Maintenance +/

  8. Slide 8: Zepzelca – A Transcription Inhibitor Leading to Tumor Inhibition

    Zepzelca – A Transcription Inhibitor Leading to Tumor Inhibition Primary Effect Secondary Effect Cancer is frequently a transcriptional disease caused by Marked effect on the tumour microenvironment by inhibiting deregulated oncogenic transcription factors the transcription and secretion of tumour-g

  9. Slide 9: 1st FDA approved drug in over 24 years for relapsed SCLC

    SCLC 1st FDA approved drug in over 24 years for Relapsed Small Cell Lung Cancer (SCLC) Standard of Care in 2L SCLC in the US 9

  10. Slide 10: Small Cell Lung Cancer (SCLC)

    Small Cell Lung Cancer (SCLC) An high unmet medical need Among all Lung Cancers Low survival rate at 5 years Limited treatment options in both the US and Europe SCLC ~15% ✦ Highly aggressive tumor ~ 62,000 in 20202 ✦ 5-year survival rate 5-10%1 ~ 30,000 in 20202 Newly diagnosed patients each year 1.

  11. Slide 11: Small Cell Lung Cancer: Development lagging behind NSCLC

    Small Cell Lung Cancer (SCLC) Development lagging behind NSCLC; FDA approvals 1st Line Cisplatin + Carboplatin + Durv or Atezo + Etoposide Etoposide Carboplatin + SCLC Etoposide 2nd Line Topotecan Pre - 1993 1996 24 years 2020 NSCLC 11

  12. Slide 12: Zepzelca (Lurbinectedin) – The SCLC Treatment Paradigm

    Zepzelca (Lurbinectedin) – The SCLC Treatment Paradigm Strong positioning opportunity 1st Line Maintenance 2nd Line 3rd Line 1st Line 2nd Line 3rd Line • Platinum/ • Platinum/ • Zepzelca Etoposide + FDA Etoposide + EMA • Topoteca • Topotecan • Atezolizuma Approved • Atezolizumab Approved n (sensitiv

  13. Slide 13: Zepzelca Already Treatment of Choice in 2L SCLC

    Zepzelca Already Treatment of Choice in 2L SCLC Zepzelca Demonstrated Efficacy in Sensitive and Resistant Small Cell Lung Cancer patients In relapsed SCLC as monotherapy under accelerated approval based on Phase 2 monotherapy data1 Overall Resistant Sensitive Decrease in tumor size in 65% patients2

  14. Slide 14: Zepzelca Already Treatment of Choice in 2L SCLC

    Zepzelca Already Treatment of Choice in 2L SCLC Low rate of AEs and manageable hematological safety profile despite low use of G-CSF 1,2 Safety: Related or Unknown Treatment Related (or Unknown) Adverse Events Adverse Events (AEs) ( >5% or Gr 3-4) Overall (n=105) n (%) Gr 1-2 Gr 3-4 Overall (n=105)

  15. Slide 15: Zepzelca: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA

    Zepzelca: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA Phase 3 (LAGOON) randomized trial Arm A Lurbinectedin 3.2 mg/m2 every 3 weeks Primary Endpoint: ✦ Relapsed SCLC Arm B ✦ One prior platinum Randomization Overall Survival containing regimen 1:1:1 Arm A vs. C ✦ CTFI ≥30 days 705 pat

  16. Slide 16: Positioning LAGOON for success

    Positioning LAGOON for success • 70% of patients to have had prior IO. There is no evidence of additive or synergistic benefit for control arm. For lurbinectedin, there are three pieces of data. • In prior trial, we allowed stable brain mets. Partly due to protocol violations this proved the worst s

  17. Slide 17: 1st line-Maintenance Study in SCLC

    SCLC 1st line-Maintenance Study in SCLC 17

  18. Slide 18: SITC 2021

    SITC 2021 Combo with IO delivers efficacy not seen for either drug as single agent • Phase I open label dose ranging trial in pts who had progressed on platinum. ECOG 0-1 • Full dose Atezo (1200 mg) + L2.5mg/m2 (n=5) followed by L3.2mg/m2 (n=21, full dose) Response N=26 CR 7.7% (2) PR 50% (13) ORR 5

  19. Slide 19: Lurbinectedin: evidences of additive/synergistic benefit with or post IO

    Lurbinectedin: evidences of additive/synergistic benefit with or post IO Basket trial: 6 of 8 had lurbi PFS ≥ PFS with prior IO including 5 CRs, 2 of which happened in 2L post PD Source: Paz-Ares, L et al. Efficacy and safety profile of lurbinectedin in 2nd-line SCLC patients: Results from a phase I

  20. Slide 20: Lurbinectedin: First line positioning

    Lurbinectedin: First line positioning Phase 3 IMforte trial for first line-maintenance SCLC Induction Phase Maintenance Phase Atezolizumab 1,200 mg q3wk + Lurbinectedin 3.2 mg/m2 q3wk Endpoints: ✦ Extensive-stage Atezolizumab + Randomization SCLC (ES-SCLC) Carboplatin + 1:1 ✦ Co-Primary: Etoposide 6

  21. Slide 21: Strategic importance of Zepzelca Phase 3s in SCLC

    Strategic importance of Zepzelca Phase 3s in SCLC Potential treatment landscape after Phase 3s 1st Line- 1st Line- 1st Line 2nd Line 1st Line 2nd Line Mantenance Mantenance ✦ Platinum/ ✦ Platinum/ Etoposide + ✦ Zepzelca + ✦ Zepzelca Etoposide + ✦ Zepzelca + • Zepzelca FDA ✦ Topotecan EMA • Topotecan

  22. Slide 22: Leiomyosarcoma

    sTS Q ZEPZELCA (lurbinectedin) Leiomyosarcoma

  23. Slide 23: Leiomyosarcoma: Incidence and treatment paradigm

    Leiomyosarcoma Incidence and treatment paradigm One of the most common soft tissue sarcoma (STS) accounting for ~ 10%-20% of all STS Incidence ~2,100(1) in USA Incidence and ~4,500(2) in Europe 1st Line 2nd Line 1st Line 2nd Line FDA ✦ Doxorubicin ✦ Trabectedin EMA ✦ Doxorubicin ✦ Trabectedin Approv

  24. Slide 24: Leiomyosarcoma

    Leiomyosarcoma Randomised P3 comparing doxorubicin +/- trabectedin in 1L metastatic or unresectable leiomyosarcoma 24

  25. Slide 25: Leiomyosarcoma

    Leiomyosarcoma Randomised P3 comparing doxorubicin +/- trabectedin in 1L metastatic or unresectable leiomyosarcoma (BICR) 25

  26. Slide 26: Zepzelca (Lurbinectedin)-Leiomyosarcoma

    Zepzelca (Lurbinectedin)-Leiomyosarcoma Phase IIb/III adaptive trial Phase IIb Phase III Doxo 50 mg/m2 + Selected • Metastatic Lurb 2.2 mg/m2 + combination* Uterine/ST LMS GCSF, D1 q3w • No prior chemo • ECOG 0-1 Primary endpoint: IDMC PFS by IRC Doxo 25 mg/m2 + N based on n ~ 120 Interim Lurb 3.2 m

  27. Slide 27: Leveraging Commercial Infrastructure in Europe

    European experience: Leveraging Commercial Infrastructure in Europe ✦ Strong KOL connections in solid tumors PharmaMar positioned as a partner of choice in Europe ✦ Navigation of EU, UK and CH regulators ✦ Logistics in place for distribution ✦ Expertise in multi-language labelling 18 Regional Partne

  28. Slide 28: Zepzelca (Lurbinectedin) – Intellectual property

    Zepzelca (Lurbinectedin) – Intellectual property Life cycle management plans under way 2023 2024 2025 2026 2027 2028+ Orphan Drug Exclusivity in SCLC New Chemical Entity Composition of Matter Patent 5 year extension to 2029 Orphan Drug Exclusivity in SCLC Composition of Matter Patent + 10 YEARS prot

  29. Slide 29: Financials

    Financials Profitable and solid and stable financial position Robust cash position (€ mn) Historical revenues evolution (€ mn) 229.8 196.3 270.0 164.9 156.0 5,0 140.6 5,0 85.8 129.4 0,3 41,0 13,0 50,3 15,7 231,8 81.6 216,5 212,6 5,5 65.0 3,1 140,3 0,2 118,9 40.4 100,7 100,8 0,2 21,3 73,0 4.2 64,8 -4

  30. Slide 30: Key Events

    Key Events Catalyst Calendar Zepzelca approved in Switzerland for SCLC  Potential lurbinectedin approvals and launches Ongoing in other countries Lurbi + Irinotecan Phase 2 topline data ~YE2023 Potential in-licensing Ongoing Phase I new product  First patient in Leiomyosarcoma  IMForte PFS Data ~

  31. Slide 31: Building the Next Phase of Growth

    Building the Next Phase of Growth 2021-2026 Leveraging proven oncology Strong Zepzelca I.P platform in new indications Zepzelca expected Clinical data Financial strength allows approvals/launches in non- IP 2023-26 broadening and accelerating EMA and EMA countries R&D engine 03 04 02 05 Profitable B

  32. Slide 32: www.pharmamar.com

    www.pharmamar.com. . a Dy i - 3 aA > = = aS - ae! ~

PharmaMar — Investor Presentation (November 2023) on 6ix